These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 30206174)

  • 41. Discovery of an antibody for pan-ebolavirus therapy.
    Furuyama W; Marzi A; Nanbo A; Haddock E; Maruyama J; Miyamoto H; Igarashi M; Yoshida R; Noyori O; Feldmann H; Takada A
    Sci Rep; 2016 Feb; 6():20514. PubMed ID: 26861827
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challenge.
    Chen G; Koellhoffer JF; Zak SE; Frei JC; Liu N; Long H; Ye W; Nagar K; Pan G; Chandran K; Dye JM; Sidhu SS; Lai JR
    ACS Chem Biol; 2014 Oct; 9(10):2263-73. PubMed ID: 25140871
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epitope-focused immunogen design based on the ebolavirus glycoprotein HR2-MPER region.
    Schoeder CT; Gilchuk P; Sangha AK; Ledwitch KV; Malherbe DC; Zhang X; Binshtein E; Williamson LE; Martina CE; Dong J; Armstrong E; Sutton R; Nargi R; Rodriguez J; Kuzmina N; Fiala B; King NP; Bukreyev A; Crowe JE; Meiler J
    PLoS Pathog; 2022 May; 18(5):e1010518. PubMed ID: 35584193
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Longitudinal Human Antibody Repertoire against Complete Viral Proteome from Ebola Virus Survivor Reveals Protective Sites for Vaccine Design.
    Khurana S; Ravichandran S; Hahn M; Coyle EM; Stonier SW; Zak SE; Kindrachuk J; Davey RT; Dye JM; Chertow DS
    Cell Host Microbe; 2020 Feb; 27(2):262-276.e4. PubMed ID: 32053790
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The induction and characterization of monoclonal antibodies specific to GP of Ebola virus.
    Tian X; Chen D; Wang H; Xu S; Zhu L; Wu X; Wu Z
    J Med Virol; 2020 Aug; 92(8):996-1006. PubMed ID: 31663613
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Broad antibody and T cell responses to Ebola, Sudan, and Bundibugyo ebolaviruses using mono- and multi-valent adjuvanted glycoprotein vaccines.
    Felgner J; Clarke E; Hernandez-Davies JE; Jan S; Wirchnianski AS; Jain A; Nakajima R; Jasinskas A; Strahsburger E; Chandran K; Bradfute S; Davies DH
    Antiviral Res; 2024 May; 225():105851. PubMed ID: 38458540
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site.
    Howell KA; Qiu X; Brannan JM; Bryan C; Davidson E; Holtsberg FW; Wec AZ; Shulenin S; Biggins JE; Douglas R; Enterlein SG; Turner HL; Pallesen J; Murin CD; He S; Kroeker A; Vu H; Herbert AS; Fusco ML; Nyakatura EK; Lai JR; Keck ZY; Foung SKH; Saphire EO; Zeitlin L; Ward AB; Chandran K; Doranz BJ; Kobinger GP; Dye JM; Aman MJ
    Cell Rep; 2016 May; 15(7):1514-1526. PubMed ID: 27160900
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mapping of conserved and species-specific antibody epitopes on the Ebola virus nucleoprotein.
    Changula K; Yoshida R; Noyori O; Marzi A; Miyamoto H; Ishijima M; Yokoyama A; Kajihara M; Feldmann H; Mweene AS; Takada A
    Virus Res; 2013 Sep; 176(1-2):83-90. PubMed ID: 23702199
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Two Distinct Lysosomal Targeting Strategies Afford Trojan Horse Antibodies With Pan-Filovirus Activity.
    Wirchnianski AS; Wec AZ; Nyakatura EK; Herbert AS; Slough MM; Kuehne AI; Mittler E; Jangra RK; Teruya J; Dye JM; Lai JR; Chandran K
    Front Immunol; 2021; 12():729851. PubMed ID: 34721393
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus.
    Howell KA; Brannan JM; Bryan C; McNeal A; Davidson E; Turner HL; Vu H; Shulenin S; He S; Kuehne A; Herbert AS; Qiu X; Doranz BJ; Holtsberg FW; Ward AB; Dye JM; Aman MJ
    Cell Rep; 2017 Apr; 19(2):413-424. PubMed ID: 28402862
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An inter-residue network model to identify mutational-constrained regions on the Ebola coat glycoprotein.
    Quinlan DS; Raman R; Tharakaraman K; Subramanian V; Del Hierro G; Sasisekharan R
    Sci Rep; 2017 Apr; 7():45886. PubMed ID: 28397835
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structural and molecular basis for Ebola virus neutralization by protective human antibodies.
    Misasi J; Gilman MS; Kanekiyo M; Gui M; Cagigi A; Mulangu S; Corti D; Ledgerwood JE; Lanzavecchia A; Cunningham J; Muyembe-Tamfun JJ; Baxa U; Graham BS; Xiang Y; Sullivan NJ; McLellan JS
    Science; 2016 Mar; 351(6279):1343-6. PubMed ID: 26917592
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mapping of Ebolavirus Neutralization by Monoclonal Antibodies in the ZMapp Cocktail Using Cryo-Electron Tomography and Studies of Cellular Entry.
    Tran EE; Nelson EA; Bonagiri P; Simmons JA; Shoemaker CJ; Schmaljohn CS; Kobinger GP; Zeitlin L; Subramaniam S; White JM
    J Virol; 2016 Sep; 90(17):7618-27. PubMed ID: 27279622
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of a micro-neutralization assay for ebolaviruses using a replication-competent vesicular stomatitis hybrid virus and a quantitative PCR readout.
    Lee SS; Phy K; Peden K; Sheng-Fowler L
    Vaccine; 2017 Oct; 35(41):5481-5486. PubMed ID: 28427845
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy.
    Fong RH; Banik SS; Mattia K; Barnes T; Tucker D; Liss N; Lu K; Selvarajah S; Srinivasan S; Mabila M; Miller A; Muench MO; Michault A; Rucker JB; Paes C; Simmons G; Kahle KM; Doranz BJ
    J Virol; 2014 Dec; 88(24):14364-79. PubMed ID: 25275138
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies.
    Ilinykh PA; Huang K; Santos RI; Gilchuk P; Gunn BM; Karim MM; Liang J; Fouch ME; Davidson E; Parekh DV; Kimble JB; Pietzsch CA; Meyer M; Kuzmina NA; Zeitlin L; Saphire EO; Alter G; Crowe JE; Bukreyev A
    Cell Host Microbe; 2020 Jun; 27(6):976-991.e11. PubMed ID: 32320678
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Role of Conserved N-Linked Glycans on Ebola Virus Glycoprotein 2.
    Lennemann NJ; Walkner M; Berkebile AR; Patel N; Maury W
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S204-9. PubMed ID: 26038399
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A shared structural solution for neutralizing ebolaviruses.
    Dias JM; Kuehne AI; Abelson DM; Bale S; Wong AC; Halfmann P; Muhammad MA; Fusco ML; Zak SE; Kang E; Kawaoka Y; Chandran K; Dye JM; Saphire EO
    Nat Struct Mol Biol; 2011 Nov; 18(12):1424-7. PubMed ID: 22101933
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Pan-Ebolavirus Monoclonal Antibody Cocktail Provides Protection Against Ebola and Sudan Viruses.
    Liu G; He S; Chan M; Zhang Z; Schulz H; Cao W; Rahim MN; Audet J; Garnett L; Wec A; Chandran K; Qiu X; Banadyga L
    J Infect Dis; 2023 Nov; 228(Suppl 7):S691-S700. PubMed ID: 37288609
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein.
    Martins K; Carra JH; Cooper CL; Kwilas SA; Robinson CG; Shurtleff AC; Schokman RD; Kuehl KA; Wells JB; Steffens JT; van Tongeren SA; Hooper JW; Bavari S
    Viral Immunol; 2015 Feb; 28(1):62-70. PubMed ID: 25514232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.